Additional File 3 of Engineered Exosomes As an in Situ DC-primed Vaccine to Boost Antitumor Immunity in Breast Cancer

Lanxiang Huang,Rong Yuan,Xuan Tang,Kezhen Yi,Qi Peng,Jian Hou,Weihuang Liu,Yuan He,Xing Gao,Chunhui Yuan,Xinghuan Wang

DOI: https://doi.org/10.6084/m9.figshare.19164452

2022-01-01

Abstract:Additional file 3: Table 2. List of primers used.

What problem does this paper attempt to address?

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Jiaoli Wang,Limin Wang,Zhendong Lin,Lisha Tao,Ming Chen

DOI: https://doi.org/10.3892/mmr.2013.1759

IF: 3.423

2014-01-01

Molecular Medicine Reports

Abstract:The incidence of lung cancer increases annually. However, the effects of the present methods for the treatment of lung cancer are extremely poor. It has been reported that exosomes from heat-stressed 3LL Lewis lung tumor cells effectively elicit systemic antitumor immunity. CD40 signaling is critical in the activation of dendritic cells (DCs), which are important in the induction of antitumor immunity. In the present study, exosomes from CD40 ligand gene-modified 3LL tumor cells (CD40L-EXO) were identified to be more immunogenic compared with control-EXO and lac Z-EXO. CD40L-EXO induced a more mature phenotype of the DCs and promoted them to secrete high levels of interleukin-12. CD40L-EXO-treated DCs induced a greater proliferation of allogeneic T cells in the mixed lymphocyte reaction. Moreover, CD40L-EXO induced robust tumor antigen-specific CD4(+) T cell proliferation ex vivo. CD40L-EXO were also extremely effective in the protective and therapeutic antitumor tests in vivo. These results indicate that CD40L-EXO may be used as an efficient vaccine for lung cancer immunotherapy.
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

Lanxiang Huang,Yuan Rong,Xuan Tang,Kezhen Yi,Peng Qi,Jinxuan Hou,Weihuang Liu,Yuan He,Xing Gao,Chunhui Yuan,Fubing Wang

DOI: https://doi.org/10.1186/s12943-022-01515-x

IF: 37.3

2022-02-11

Molecular Cancer

Abstract:Abstract Background Dendritic cells (DCs) are central for the initiation and regulation of innate and adaptive immunity in the tumor microenvironment. As such, many kinds of DC-targeted vaccines have been developed to improve cancer immunotherapy in numerous clinical trials. Targeted delivery of antigens and adjuvants to DCs in vivo represents an important approach for the development of DC vaccines. However, nonspecific activation of systemic DCs and the preparation of optimal immunodominant tumor antigens still represent major challenges. Methods We loaded the immunogenic cell death (ICD) inducers human neutrophil elastase (ELANE) and Hiltonol (TLR3 agonist) into α-lactalbumin (α-LA)-engineered breast cancer-derived exosomes to form an in situ DC vaccine (HELA-Exos). HELA-Exos were identified by transmission electron microscopy, nanoscale flow cytometry, and Western blot analysis. The targeting, killing, and immune activation effects of HELA-Exos were evaluated in vitro. The tumor suppressor and immune-activating effects of HELA-Exos were explored in immunocompetent mice and patient-derived organoids. Results HELA-Exos possessed a profound ability to specifically induce ICD in breast cancer cells. Adequate exposure to tumor antigens and Hiltonol following HELA-Exo-induced ICD of cancer cells activated type one conventional DCs (cDC1s) in situ and cross-primed tumor-reactive CD8 + T cell responses, leading to potent tumor inhibition in a poorly immunogenic triple negative breast cancer (TNBC) mouse xenograft model and patient-derived tumor organoids. Conclusions HELA-Exos exhibit potent antitumor activity in both a mouse model and human breast cancer organoids by promoting the activation of cDC1s in situ and thus improving the subsequent tumor-reactive CD8 + T cell responses. The strategy proposed here is promising for generating an in situ DC-primed vaccine and can be extended to various types of cancers. Graphic Abstract Scheme 1. Schematic illustration of HELA-Exos as an in situ DC-primed vaccine for breast cancer. (A) Allogenic breast cancer-derived exosomes isolated from MDA-MB-231 cells were genetically engineered to overexpress α-LA and simultaneously loaded with the ICD inducers ELANE and Hiltonol (TLR3 agonist) to generate HELA-Exos. (B) Mechanism by which HELA-Exos activate DCs in situ in a mouse xenograft model ofTNBC. HELA-Exos specifically homed to the TME and induced ICD in cancer cells, which resulted in the increased release of tumor antigens, Hiltonol, and DAMPs, as well as the uptake of dying tumor cells by cDC1s. The activated cDC1s then cross-primed tumor-reactive CD8+ T cell responses. (C) HELA-Exos activated DCs in situ in the breast cancer patient PBMC-autologous tumor organoid coculture system. Abbreviations: DCs: dendritic cells; α-LA: α-lactalbumin; HELA-Exos: Hiltonol-ELANE-α-LA-engineered exosomes; ICD: immunogenic cell death; ELANE: human neutrophil elastase; TLR3: Toll-like receptor 3; TNBC: triple-negative breast cancer; TME: tumor microenvironment; DAMPs: damage-associated molecular patterns; cDC1s: type 1 conventional dendritic cells; PBMCs: peripheral blood mononuclear cells

oncology,biochemistry & molecular biology
The Antitumor Effect of Gene-Engineered Exosomes in the Treatment of Brain Metastasis of Breast Cancer.

Minchen Liu,Yulan Hu,Guiqian Chen

DOI: https://doi.org/10.3389/fonc.2020.01453

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Strategies for treating brain metastases of breast cancer have demonstrated limited efficacy due to the blood-brain barrier (BBB). Gene therapy could improve the efficacy of chemotherapeutic drugs. Exosomes derived from the mesenchymal stem cells (MSCs) are small membrane-based gene vectors that can pass through the BBB. CXCR4 is the most commonly found chemokine receptor in human cancer cells. Furthermore, the SDF-1/CXCR4 axis plays an important role in the homing of MSCs for tumor cell diffusion and metastasis. TRAIL can selectively induce apoptosis in transformed cells without significant toxic side effects in normal tissues. In this study, exosomes were isolated from MSCCXCR4+TRAIL transduced with CXCR4 and TRAIL using a lentiviral vector. Synergistic antitumor study showed that exosomeCXCR4+TRAIL exerted significant activity as a cooperative agent with carboplatin in an MDA-MB-231Br SCID mouse model, potentially engendering a novel strategy for advancing the treatment of brain metastases of breast cancer. Based on this study, further investigation of the effect of the vector on BBB and inducing apoptosis of brain tumors is warranted. In addition, the safety of the vector in animals during the treatment needs to be evaluated.
Increasing the Immune Activity of Exosomes: the Effect of Mirna-Depleted Exosome Proteins on Activating Dendritic Cell/cytokine-Induced Killer Cells Against Pancreatic Cancer.

Ri-Sheng Que,Cheng Lin,Guo-Ping Ding,Zheng-Rong Wu,Li-Ping Cao

DOI: https://doi.org/10.1631/jzus.b1500305

2016-01-01

Journal of Zhejiang University SCIENCE B

Abstract:BACKGROUND:Tumor-derived exosomes were considered to be potential candidates for tumor vaccines because they are abundant in immune-regulating proteins, whereas tumor exosomal miRNAs may induce immune tolerance, thereby having an opposite immune function.OBJECTIVE:This study was designed to separate exosomal protein and depleted exosomal microRNAs (miRNAs), increasing the immune activity of exosomes for activating dendritic cell/cytokine-induced killer cells (DC/CIKs) against pancreatic cancer (PC).METHODS:PC-derived exosomes (PEs) were extracted from cultured PANC-1 cell supernatants and then ruptured; this was followed by ultrafiltered exosome lysates (UELs). DCs were stimulated with lipopolysaccharide (LPS), PE, and UEL, followed by co-culture with CIKs. The anti-tumor effects of DC/CIKs against PC were evaluated by proliferation and killing rates, tumor necrosis factor-α (TNF-α) and perforin secretion. Exosomal miRNAs were depleted after lysis and ultrafiltration, while 128 proteins were retained, including several immune-activating proteins.RESULTS:UEL-stimulated DC/CIKs showed a higher killing rate than LPS- and PE-stimulated DC/CIKs.CONCLUSIONS:miRNA-depleted exosome proteins may be promising agonists for specifically activating DC/CIKs against PC.
Abstract 5077: Engineering dendritic cell-derived exosomes forbrain metastases immunotherapy

Hao-Nien Chen,Xiangliang Yuan,Yimin Duan,Yi Xiao,Shao-Ping Yang,DIhua Yu

DOI: https://doi.org/10.1158/1538-7445.am2023-5077

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Brain metastases (BrMs) represent an unmet challenge for the therapy of most aggressive cancers owing to the extremely poor survival and the limited efficacy of available therapies. Currently, NO curative therapy for breast cancer BrM (BCBrM) is available and we urgently need to develop new and effective therapies. Immune checkpoint therapies (ICT) have revolutionized cancer treatment, but are generally unsuccessful in treating BrMs, including BCBrM. A crucial reason for this is the unique brain immune microenvironment with low antigen exposure/presentation in BrMs and fewer antigen-specific T cells in the brain parenchyma. The priming and activation of antigen-specific T cells require professional antigen-presenting dendritic cells (DCs) for effective antigen presentation through multifaceted communication between DCs and T cells by direct intercellular contact and indirect distant communication via exosomes and other means. DC-derived exosomes (DCEXs) carry functional MHC-I/peptide complexes (pMHC-I) and costimulatory molecules, hence facilitating systemic T cell immune responses. DCEXs have been developed as immunotherapies which exhibit advantages over DC-based immunotherapies. However, DCEXs in ongoing clinical trials showed limited efficacy. We found that increased non-receptor protein tyrosine phosphatase SHP1, a DC-intrinsic inhibitory checkpoint, in monocyte-derived DCs (MoDCs) ex vivo led to DC exhaustion that limits DCEXs function resulting in poor systemic T cells stimulation in vivo. To improve DCEXs functions, we developed next-generation DCEXs by genetic knockout of SHP1 in DCs from which DCEXs (iSHP1-DCEXs) were isolated. Remarkably, the modified iSHP1-DCEXs exhibited significantly increased pMHC-I expression and more effectively improved T cell proliferation compared to control DCEXs, indicating a greater capacity of antigen presentation of engineered iSHP1-DCEXs. In the EO771-OVA mammary tumor cells-bearing mouse model, iSHP1-DCEXs treatment greatly increased tumor infiltration of OVA antigen-specific CD8+ T (OT-1) cells resulting in tumor inhibition and prolonged mouse survival, indicating that iSHP1-DCEXs elicited an effective and specific antitumor immunity in vivo. Moreover, combining iSHP1-DCEXs with anti-PD1 Ab yielded a strong syngenetic therapeutic response in mice bearing the anti-PD1-resistant EO771 tumors, as indicated by delayed tumor growth and prolonged survival. importantly, iSHP1-DCEXs also significantly increased tumor-infiltrating antigen-specific T cells and synergized with PD-1 Ab leading to tumors clearance in mice bearing the B16-GMCSF melanoma. To further test the iSHP1-DCEXs effect in BCBrM, we co-injected EO771-OVA and iSHP1-DCEXs into mice and found that iSHP1-DCEXs inhibited BrM. Together, the engineered iSHP1-DCEXs offer a promising option to generate a potent antigen-specific T cell immune response for BCBrM inhibition. Citation Format: Hao-Nien Chen, Xiangliang Yuan, Yimin Duan, Yi Xiao, Shao-Ping Yang, DIhua Yu. Engineering dendritic cell-derived exosomes forbrain metastases immunotherapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5077.

oncology
Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Shengming Dai,Xiangyang Zhou,Baomei Wang,Qingqing Wang,Yangxin Fu,Taoyong Chen,Tao Wan,Yizhi Yu,Xuetao Cao

DOI: https://doi.org/10.1007/s00109-006-0102-0

2006-01-01

Abstract:Dendritic cells (DC)-derived or tumor-derived exosomes are a population of nanometer sized membrane vesicles that can induce specific anti-tumor immunity. However, the immunogenic potential and efficiency of exosomes-based tumor vaccine are not satisfactory enough to achieve a curative effect in clinical trials. In this article we investigated whether IL-18 genetic modification of tumor cells can increase the efficacy of exosomes derived from IL-18 gene-modified tumor cells. We transfected carcinoembryonic antigen (CEA)-expressing tumor cells with a recombinant adenovirus encoding human IL-18 (AdhIL-18) and prepared the exosomes, Exo/IL-18, from IL-18 gene-modified tumor cells. We found that Exo/IL-18 naturally contain CEA and bioactive IL-18. Moreover, Exo-IL-18 are potent in chemoattracting DC and T cells, enhancing the proliferation and Th1 cytokine release of PBMC, and promoting the phenotypic and functional maturation of DC. Furthermore, Exo/IL-18-pulsed DC are quite potent to induce HLA-A*0201-restricted, CEA-specific CD8 + CTL from the PBMC of HLA-A*0201 CEA + cancer patients in vitro. In almost all of these experiments, Exo/IL-18 show more potent functions than the conventionally prepared exosomes derived from parent tumor cells without IL-18 gene modification. Our findings suggest that Exo/IL-18 has more potent capability to induce specific anti-tumor immunity, and our strategy of IL-18 modification of exosomes is a feasible approach to develop exosomes-based tumor vaccines.
Abstract 7251: Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy

Xiabing Lyu,Tomoyoshi Yamano,Shota Imai,Toan Van Le,Rikinari Hanayama

DOI: https://doi.org/10.1158/1538-7445.am2024-7251

IF: 11.2

2024-03-31

Cancer Research

Abstract:Tumor immunotherapy, including immune checkpoint therapy, CAR T cell therapy, and TCR-T cell therapy, has made significant progress in the treatment of cancer. Recently, newly developed nanomaterials have also been applied to anti-tumor immunotherapy. Among them, extracellular vesicles (EVs) have been well-engineered in recent years due to their low immunogenicity, high stability, and wide distribution in biological fluids. Despite the recent development of several EVs-based cancer immunotherapies, their clinical efficacy remains limited. In this study, we have developed engineered EVs designed to mimic the function of antigen-presenting cells, which can co-deliver multiple immune-activation signals to tumor-associated T cells. We named these vesicles Antigen-presenting Extracellular Vesicles (AP-EVs). AP-EVs express a high level of MHC I-peptide complexes, costimulatory molecules, and surface-bound cytokines, allowing for the simultaneous presentation of multiple immune modulators to antigen-specific CD8+ T cells. AP-EVs promote the clonal expansion and differentiation of antigen-specific cytotoxic T lymphocytes, resulting in potent anticancer immune responses. Notably, our findings indicate that combination therapy involving AP-EVs and anti-PD-1 yields superior anticancer immunity against established tumors compared to anti-PD-1 monotherapy. This synergistic effect underscores the potential of our engineered EVs as a novel and highly effective strategy for cancer immunotherapy. Citation Format: Xiabing Lyu, Tomoyoshi Yamano, Shota Imai, Toan Van Le, Rikinari Hanayama. Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7251.

oncology
Abstract 5492: Determining effects of the CD206 positive M2 macrophage depleting engineered exosome in combination with anti PD1 therapy in breast tumor

Mahrima Parvin,Mohammad H. Rashid,Ahmet Alptekin,Ali S. Arbab

DOI: https://doi.org/10.1158/1538-7445.am2023-5492

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Introduction: Triple negative breast cancer (TNBC) subtype of breast cancer, which lacks molecular markers such as HER2 and estrogen/progesterone receptors, has limited treatment options. Exosomes are nano-sized (30-150 nm) spherical vesicles, derived from the endosomal system for intercellular communications, can be engineered to express targeting peptides to target specifically CD206 positive M2 macrophage. Investigators have used either synthetic nanoparticles or fusion protein to deliver Fc-IgG2b to initiate Antibody dependent cellular cytotoxicity (ADCC) but reports are showing a lack of ADCC following tagging with gold nanoparticles. To overcome this, in our lab, we developed engineered exosomes in non-tumorous cells, HEK293, to carry therapeutic Fc-mIgG2b to enhance ADCC and to carry peptide to deplete CD206+ M2 macrophages. We investigated the effectiveness of engineered therapeutic exosomes to target and deplete immunosuppressive CD206+ M2 macrophages in TNBC in combination with anti PD-1. Methods: In this study, we developed syngeneic metastatic TBNC model (luciferase + 4T1 cells in Balb/c) by implantation of 50K 4T1-luci cells in fat pad. On day 1 of tumor implantation, animals were treated with vehicle, engineered exosomes, anti-PD1 plus engineered exosomes, 2 dose/week for 3 weeks. They were euthanized 1 day after the last dose of treatment. Single-cell suspension was made from the primary TME, lung, and spleen. Using flow cytometry surfaces markers were investigated to determine different T-cell and myeloid cell populations. Results: We observed very surprising results following three weeks of therapies. Although the number of cytotoxic T-cells was significantly higher in the primary and metastatic TME in exosome-treated animals, there was also an increased number of proliferative T reg cells. The number of CD8+ cells was decreased following concurrent therapy with an anti-PD1 antibody. Most interestingly, lung tissue macrophages (CD11c) showed significantly increased PD-L1 expression following exosomes and anti PD1 with engineered exosomes therapies. Conclusion: This study demonstrates that treatment with engineered therapeutic exosome targeting M2 macrophages with anti PD-1 could be utilized effectively. This study will also make a greater impact in exosome engineering based targeted therapy and will open new arena to target and deplete pathogenic cell in different tumors using engineered exosome. Citation Format: Mahrima Parvin, Mohammad H. Rashid, Ahmet Alptekin, Ali S. Arbab. Determining effects of the CD206 positive M2 macrophage depleting engineered exosome in combination with anti PD1 therapy in breast tumor. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5492.

oncology
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Xue-Bin Ran,Ling-Wen Ding,Qiao-Yang Sun,Henry Yang,Jonathan W. Said,Lao Zhentang,Vikas Madan,Pushkar Dakle,Jin-Fen Xiao,Xinyi Loh,Ying Li,Liang Xu,Xiao-Qiang Xiang,Ling-Zhi Wang,Boon Cher Goh,De-Chen Lin,Wee Joo Chng,Soo-Yong Tan,Sudhakar Jha,H. Phillip Koeffler

DOI: https://doi.org/10.1158/0008-5472.22432644.v1

2023-01-01

Abstract:<p>This file contains supplementary methods, Figs. S1 to S6 and Tables S1 to S5.</p>
Engineered Tumor-Derived Extracellular Vesicles: Potentials in Cancer Immunotherapy

Adeleh Taghikhani,Farzin Farzaneh,Farzaneh Sharifzad,Soura Mardpour,Marzieh Ebrahimi,Zuhair Mohammad Hassan

DOI: https://doi.org/10.3389/fimmu.2020.00221

IF: 7.3

2020-03-06

Frontiers in Immunology

Abstract:Exosomes are nano vesicles from the larger family named Extracellular Vesicle (EV)s which are released by various cells including tumor cells, mast cells, dendritic cells, B lymphocytes, neurons, adipocytes, endothelial cells, and epithelial cells. They are considerable messengers that can exchange proteins and genetic materials between the cells. Within the past decade, Tumor derived exosomes (TEX) have been emerged as important mediators in cancer initiation, progression and metastasis as well as host immune suppression and drug resistance. Although tumor derived exosomes consist of tumor antigens and several Heat Shock Proteins such as HSP70 and HSP90 to stimulate immune response against tumor cells, they contain inhibitory molecules like Fas ligand (Fas-L), Transforming Growth Factor Beta (TGF-β) and Prostaglandin E2 (PGE2) leading to decrease the cytotoxicity and establish immunosuppressive tumor microenvironment (TME). To bypass this problem and enhance immune response, some macromolecules such as miRNAs, HSPs and activatory ligands have been recognized as potent immune inducers that could be used as anti-tumor agents to construct a nano sized tumor vaccine. Here, we discussed emerging engineered exosomes as a novel therapeutic strategy and considered the associated challenges.

immunology
Engineered Antler Stem Cells Derived Exosomes Potentiate Anti-Tumor Efficacy of Immune Checkpoint Inhibitor by Reprogramming Immunosuppressive Tumor Microenvironment

Min Yang,Li Pu,Shuiyue Yang,Ze Chen,Jia Guo,Ying Liu,Shuzhuo Chang,Yinghua Peng

DOI: https://doi.org/10.1016/j.cej.2023.147421

IF: 15.1

2023-01-01

Chemical Engineering Journal

Abstract:Immunotherapy has received extensive attention in the field of tumor treatment, but the existence of immunosuppressive tumor microenvironment (TME) leads to the suboptimal therapeutic effect, which is the main obstacle that restricts the clinical application of immunotherapy. Therefore, there is an urgent demand to reverse the immunosuppressive TME to improve the anti-tumor efficacy. In this work, engineered antler stem cells (ASCs)-derived exosomes were developed by modified with M2 macrophage targeting peptide (M2Pep) on their surface and encapsulated with toll-like receptor 3 (TLR3) agonist poly(I:C) termed as M2Pep-Exo(pIC) for enhanced tumor immunotherapy. The natural nanocarrier exosomes derived from ASCs hold great potential to suppress tumor growth and are easily to be obtained because of the tumor resistance and annual regeneration characteristics of the antler. Due to the engineering of M2Pep, the M2Pep-Exo(pIC) achieved improved enrichment in tumor tissue. The M2Pep-Exo(pIC) could boost systemic anti-tumor immune responses through repolarizing tumor associated macrophages (TAMs) and promoting dendritic cells maturation, leading to an increased cytotoxic CD8(+) T cells infiltration in tumor site for effective anti-tumor therapy. Moreover, the combination of M2Pep-Exo(pIC) with the PD-L1 antibody not only arrested the progression of primary tumor, but also inhibited tumor metastasis. These findings highlight a promising approach to enhance PD-L1 checkpoint blockade activity through remodeling immunosuppressive TME, thus achieving a robust immunotherapy effect for solid tumors.
Gene Engineered Exosome Reverses T Cell Exhaustion in Cancer Immunotherapy

Peishan Li,Ying Xie,Jinling Wang,Chunjie Bao,Jialun Duan,Yixuan Liu,Qian Luo,Jiarui Xu,Yuxin Ren,Min Jiang,Jianwei Li,Haitao Guo,Huihui Zhao,Guiling Wang,Yanqin Liang,Wanliang Lu

DOI: https://doi.org/10.1016/j.bioactmat.2024.01.008

IF: 18.9

2024-01-01

Bioactive Materials

Abstract:Cancer patients by immune checkpoint therapy have achieved long-term remission, with no recurrence of clinical symptoms of cancer for many years. Nevertheless, more than half of cancer patients are not responsive to this therapy due to immune exhaustion. Here, we report a novel gene engineered exosome which is rationally designed by engineering PD1 gene and simultaneously enveloping an immune adjuvant imiquimod (PD1-Imi Exo) for boosting response of cancer immune checkpoint blockage therapy. The results showed that PD1-Imi Exo had a vesicular round shape (approximately 139 nm), revealed a significant targeting and a strong binding effect with both cancer cell and dendritic cell, and demonstrated a remarkable therapeutic efficacy in the melanoma-bearing mice and in the breast cancer-bearing mice. The mechanism was associated with two facts that PD1-Imi Exo blocked the binding of CD8+ T cell with cancer cell, displaying a PD1/PDL1 immune checkpoint blockage effect, and that imiquimod released from PD1-Imi Exo promoted the maturation of immature dendritic cell, exhibiting a reversing effect on the immune exhaustion through activating and restoring function of CD8+ T cell. In conclusion, the gene engineered exosome could be used for reversing T cell exhaustion in cancer immunotherapy. This study also offers a promising new strategy for enhancing PD1/PDL1 therapeutic efficacy, preventing tumor recurrence or metastasis after surgery by rebuilding the patients' immunity, thus consolidating the overall prognosis.
Engineered Exosomes-Based Photothermal Therapy with MRI/CT Imaging Guidance Enhances Anticancer Efficacy through Deep Tumor Nucleus Penetration

Min Yang,Xiaohui Wang,Fang Pu,Ying Liu,Jia Guo,Shuzhuo Chang,Guoying Sun,Yinghua Peng

DOI: https://doi.org/10.3390/pharmaceutics13101593

IF: 6.525

2021-09-30

Pharmaceutics

Abstract:Exosomes, as natural nanovesicles, have become a spotlight in the field of cancer therapy due to their reduced immunogenicity and ability to overcome physiological barriers. However, the tumor targeting ability of exosomes needs to be improved before its actual application. Herein, a multiple targeted engineered exosomes nanoplatform was constructed through rare earth element Gd and Dy-doped and TAT peptide-modified carbon dots (CDs:Gd,Dy-TAT) encapsulated into RGD peptide engineered exosomes (Exo-RGD), which were used to enhance the effect of cancer imaging diagnosis and photothermal therapy. In vitro and in vivo experiments showed that the resulting CDs:Gd,Dy-TAT@Exo-RGD could effectively accumulate at cancer site with an increased concentration owing to the targeting peptides modification and exosomes encapsulation. The tumor therapy effects of mice treated with CDs:Gd,Dy-TAT@Exo-RGD were heightened compared with mice from the CDs:Gd,Dy control group. After intravenous injection of CDs:Gd,Dy-TAT@Exo-RGD into tumor-bearing mice, the temperature of tumors rose to above 50 °C under NIR irradiation and the localized hyperpyrexia induced by CDs could remarkably ablate tumors. The survival rate of the mice was 100% after 60 days. In addition, the CDs:Gd,Dy-TAT@Exo-RGD exhibited higher MRI/CT imaging contrast enhancement of tumor sites than that of CDs:Gd,Dy. Our study identified that engineered exosomes are a powerful tool for encapsulating multiple agents to enhance cancer theranostic efficiency and provide insight into precise personalized nanomedicine.

pharmacology & pharmacy
Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy

Xuyu Li,Shuaicheng He,Ban Luo,Puze Li,Xue Chen,Meichan Wu,Cheng Song,Chao Liu,Tian Yang,Xiaojuan Zhang,Xiangliang Yang,Jun Hu

DOI: https://doi.org/10.1002/smll.202303541

IF: 13.3

2023-08-24

Small

Abstract:Engineering strategy is employed to obtain Te nanoparticles‐encapsulated extracellular vesicles with high heat shock protein 70 expression. These nanoparticles can damage tumor cells and induce immunogenic cell death under light drive, subsequently capturing more tumor‐associated antigens. Dendritic cells present more tumor‐associated antigens to CD8+ T cells after uptake of nanoparticles, achieving enhanced anti‐tumor immunity. Extracellular vesicles (EVs) have emerged as potential tools for tumor‐target therapy accompanied with activating anticancer immune responses by serving as an integrated platform, but usually suffered from the limited cross presentation of tumor‐associated antigen by dendritic cells (DCs). Here, a straightforward engineering strategy to construct heat shock proteins 70 (HSP70) highly expressed EVs incapsulated with Te nanoparticles (Te@EVsHSP70) for tumor photothermal therapy triggering improved immunotherapy is proposed. Tumor cells are firstly used as bioreactors for intracellular synthesis of Te nanoparticles, and NIR irradiation is subsequently introduced to upregulate the expression of HSP70 to give engineered Te@EVsHSP70 through exocytosis. Te@EVsHSP70 exhibits excellent photothermal performance and enhanced tumor antigen capture capability, which induces significant immunogenic death of tumor cells and improves DCs maturation both in vitro and in vivo. Thus, the engineered EVs demonstrate superior antitumor efficacy through photothermal effect and following provoked antitumor immune responses. This work provides a facile method to fabricate multifunctional EVs‐based drug delivery system for improving photothermal‐triggered tumor immunotherapy.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy (Small 49/2023)

Xuyu Li,Shuaicheng He,Ban Luo,Puze Li,Xue Chen,Meichan Wu,Cheng Song,Chao Liu,Tian Yang,Xiaojuan Zhang,Xiangliang Yang,Jun Hu

DOI: https://doi.org/10.1002/smll.202370416

IF: 13.3

2023-12-10

Small

Abstract:Engineered Extracellular Vesicles Extracellular vesicles (EVs)‐based tumor immunotherapy has usually suffered from the limited cross presentation of tumor‐associated antigen by dendritic cells (DCs). In article number 2303541, Jun Hu, Xiangliang Yang, and co‐workers propose a straightforward engineering strategy to construct heat shock proteins 70 (HSP70) highly expressed EVs, which could capture tumor related antigens through the C‐terminal polypeptide binding domain of HSP70 molecules and then stimulate the maturation of DCs via binding to the surface receptors of DCs.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
DC-Based Vaccines for Cancer Immunotherapy

Chunmei Fu,Li Zhou,Qing-Sheng Mi,Aimin Jiang

DOI: https://doi.org/10.3390/vaccines8040706

2020-11-26

Vaccines

Abstract:As the sentinels of the immune system, dendritic cells (DCs) play a critical role in initiating and regulating antigen-specific immune responses. Cross-priming, a process that DCs activate CD8 T cells by cross-presenting exogenous antigens onto their MHCI (Major Histocompatibility Complex class I), plays a critical role in mediating CD8 T cell immunity as well as tolerance. Current DC vaccines have remained largely unsuccessful despite their ability to potentiate both effector and memory CD8 T cell responses. There are two major hurdles for the success of DC-based vaccines: tumor-mediated immunosuppression and the functional limitation of the commonly used monocyte-derived dendritic cells (MoDCs). Due to their resistance to tumor-mediated suppression as inert vesicles, DC-derived exosomes (DCexos) have garnered much interest as cell-free therapeutic agents. However, current DCexo clinical trials have shown limited clinical benefits and failed to generate antigen-specific T cell responses. Another exciting development is the use of naturally circulating DCs instead of in vitro cultured DCs, as clinical trials with both human blood cDC2s (type 2 conventional DCs) and plasmacytoid DCs (pDCs) have shown promising results. pDC vaccines were particularly encouraging, especially in light of promising data from a recent clinical trial using a human pDC cell line, despite pDCs being considered tolerogenic and playing a suppressive role in tumors. However, how pDCs generate anti-tumor CD8 T cell immunity remains poorly understood, thus hindering their clinical advance. Using a pDC-targeted vaccine model, we have recently reported that while pDC-targeted vaccines led to strong cross-priming and durable CD8 T cell immunity, cross-presenting pDCs required cDCs to achieve cross-priming in vivo by transferring antigens to cDCs. Antigen transfer from pDCs to bystander cDCs was mediated by pDC-derived exosomes (pDCexos), which similarly required cDCs for cross-priming of antigen-specific CD8 T cells. pDCexos thus represent a new addition in our arsenal of DC-based cancer vaccines that would potentially combine the advantage of pDCs and DCexos.

immunology,medicine, research & experimental
PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Xinyue Dai,Zhaoshuo Wang,Miao Fan,Huifang Liu,Xinjian Yang,Xueyi Wang,Xiaohan Zhou,Yunlu Dai,Jinchao Zhang,Zhenhua Li

DOI: https://doi.org/10.1016/j.vesic.2022.100012

2022-01-01

Extracellular Vesicle

Abstract:Tumor immunotherapy significantly rewards antigen-specific T-cell responses, which have been recognized as the foundation of adaptive immune responses. However, due to the immunosuppressive effects of the tumor microenvironment, it is still hard to activate T cells in situ. Especially, antigen-specific T cell activity is further limited as tumor cells can evade T cell attack via PD-1/PD-L1 axis. During this work, we used a dendritic cells (DCs)-derivate exosome vaccine to build an immunotherapeutic system that can simultaneously mediate antigenic T cell activity by carrying T cells activating CD80 and MHC to induce humoral immunity. More importantly, in order to interrupt tumor immune escape, we also engineered anti-PD-L1 antibodies (aPD-L1) to block PD-1/PD-L1 axis at the same time. Our antigens-feeding DCs-exosomes with aPD-L1 engineering represents a promising strategy for enhanced cancer immunotherapy by robust activating T cells. The outcomes demonstrated that Exo-OVA-aPD-L1 was successful in inhibiting the growth, recurrence, and metastasis of melanoma.
Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Jilong Cao,Gang Lv,Fang Wei

DOI: https://doi.org/10.1002/ctm2.1645

Abstract:Background: Breast cancer remains a global health challenge, necessitating innovative therapeutic approaches. Immunomodulation and immunotherapy have emerged as promising strategies for breast cancer treatment. Engineered exosomes are the sort of exosomes modified with surface decoration and internal therapeutic molecules. Through suitable modifications, engineered exosomes exhibit the capability to overcome the limitations associated with traditional therapeutic approaches. This ability opens up novel avenues for the development of more effective, personalized, and minimally invasive interventions. Main body: In this comprehensive review, we explore the molecular insights and therapeutic potential of engineered exosomes in breast cancer. We discuss the strategies employed for exosome engineering and delve into their molecular mechanisms in reshaping the immune microenvironment of breast cancer. Conclusions: By elucidating the contribution of engineered exosomes to breast cancer immunomodulation, this review underscores the transformative potential of this emerging field for improving breast cancer therapy. Highlights: Surface modification of exosomes can improve the targeting specificity. The engineered exosome-loaded immunomodulatory cargo regulates the tumour immune microenvironment. Engineered exosomes are involved in the immune regulation of breast cancer.
Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy

Kaifan Liang,Yinzhe Sun,Laozhi Xie,Yipu Liu,Yang You,Jianpei Xu,Fenfen Ma,Yukun Huang,Qingxiang Song,Wenze Xiao,Jianming Huang,Xiaoling Gao,Jun Chen

DOI: https://doi.org/10.1021/acsnano.4c01050

IF: 17.1

2024-02-27

ACS Nano

Abstract:Tumor cell-derived cancer nanovaccines introduce tumor cell-derived components as functional units that endow the nanovaccine systems with some advantages, especially providing all potential tumor antigens. However, cumbersome assembly steps, potential risks of exogenous adjuvants, as well as insufficient lymph node (LN) targeting and dendritic cell (DC) internalization limit the efficacy and clinical translation of existing tumor cell-derived cancer nanovaccines. Herein, we introduced an endoplasmic reticulum (ER) stress inducer α-mangostin (αM) into tumor cells through poly(d, l-lactide-co-glycolide) nanoparticles and harvested biologically self-assembled tumor cell-derived cancer nanovaccines (αM-Exos) based on the biological process of tumor cell exocytosing nanoparticles through tumor-derived exosomes (TEXs). Besides presenting multiple potential antigens, αM-Exos inherited abundant 70 kDa heat shock proteins (Hsp70s) upregulated by ER stress, which can not only act as endogenous adjuvants but also improve LN targeting and DC internalization. Following subcutaneous injection, αM-Exos efficiently migrated to LNs and was expeditiously endocytosed by DCs, delivering tumor antigens and adjuvants to DCs synchronously, which then powerfully triggered antitumor immune responses and established long-term immune memory. Our study exhibited an all-in-one biologically self-assembled tumor cell-derived cancer nanovaccine platform, and the fully featured cancer nanovaccines assembled efficiently through this platform are promising for desirable cancer immunotherapy.
Engineered extracellular vesicles and their mimetics for cancer immunotherapy

Chunping Liu,Yichao Wang,Longmei Li,Dongyue He,Jiaxin Chi,Qin Li,Yixiao Wu,Yunxuan Zhao,Shihui Zhang,Lei Wang,Zhijin Fan,Yuhui Liao

DOI: https://doi.org/10.1016/j.jconrel.2022.05.062

IF: 11.467

2022-07-30

Journal of Controlled Release

Abstract:Extracellular vesicles (EVs) are heterogeneous membranous vesicles secreted by living cells that are involved in many physiological and pathological processes as intermediaries for intercellular communication and molecular transfer. Recent studies have shown that EVs can regulate the occurrence and development of tumors by transferring proteins, lipids and nucleic acids to immune cells as signaling molecules. As a new diagnostic biomarker and drug delivery system, EVs have broad application prospects in immunotherapy. In addition, the breakthrough of nanotechnology has promoted the development and exploration of engineered EVs for immune-targeted therapy. Herein, we review the uniqueness of EVs in immune regulation and the engineering strategies used for immunotherapy and highlight the logic of their design through typical examples. The present situation and challenges of clinical transformation are discussed, and the development prospects of EVs in immunotherapy are proposed. The goal of this review is to provide new insights into the design of immune-regulatory EVs and expand their application in cancer immunotherapy.

pharmacology & pharmacy,chemistry, multidisciplinary

Additional File 3 of Engineered Exosomes As an in Situ DC-primed Vaccine to Boost Antitumor Immunity in Breast Cancer

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

The Antitumor Effect of Gene-Engineered Exosomes in the Treatment of Brain Metastasis of Breast Cancer.

Increasing the Immune Activity of Exosomes: the Effect of Mirna-Depleted Exosome Proteins on Activating Dendritic Cell/cytokine-Induced Killer Cells Against Pancreatic Cancer.

Abstract 5077: Engineering dendritic cell-derived exosomes forbrain metastases immunotherapy

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Abstract 7251: Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy

Abstract 5492: Determining effects of the CD206 positive M2 macrophage depleting engineered exosome in combination with anti PD1 therapy in breast tumor

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Engineered Tumor-Derived Extracellular Vesicles: Potentials in Cancer Immunotherapy

Engineered Antler Stem Cells Derived Exosomes Potentiate Anti-Tumor Efficacy of Immune Checkpoint Inhibitor by Reprogramming Immunosuppressive Tumor Microenvironment

Gene Engineered Exosome Reverses T Cell Exhaustion in Cancer Immunotherapy

Engineered Exosomes-Based Photothermal Therapy with MRI/CT Imaging Guidance Enhances Anticancer Efficacy through Deep Tumor Nucleus Penetration

Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy

Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy (Small 49/2023)

DC-Based Vaccines for Cancer Immunotherapy

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy

Engineered extracellular vesicles and their mimetics for cancer immunotherapy